Richard Dunne, MD

Medical Oncoligst
University of Rochester, United States

Presentation(s):

• 43: An Update On The Phase I Study to Evaluate the Safety and Tolerability of SX-682 in Combination with Anti-PD1 as Maintenance Therapy for Unresectable Pancreatic Adenocarcinoma

  Thursday, March 21, 2024
  2:12pm – 2:22pm ET